01 Apr , 2026 By : Debdeep Gupta
Granules India shares gained 2 percent in the early trade on April 1 after its wholly owned subsidiary, Granules Life Sciences, received a Voluntary Action Indicated (VAI) classification following an inspection by the United States Food and Drug Administration.
At 09:18am, Granules India was quoting at Rs 634.50, up Rs 13.35, or 2.15 percent, on the BSE.
The inspection of its manufacturing facility in Shamirpet, Telangana, was conducted between December 15 and 19, 2025, covering current Good Manufacturing Practice (cGMP) and pre-approval inspection (PAI) for oral solid dosage operations.
The Establishment Inspection Report (EIR) has been issued, and the inspection has now been closed with no regulatory action recommended.
Earlier in the month of March, its US step-down subsidiary, Granules Consumer Health LLC (a wholly-owned subsidiary of Granules Pharmaceuticals, Inc.), has received an Establishment Inspection Report (EIR) with a No Action Indicated (NAI) status from the USFDA following an inspection at its Manassas, Virginia packaging facility conducted between December 1 and 3, 2025.
The share price jumped more than 25 percent in the last nine months.
In the previous trading session, the share closed at Rs 621.15, down Rs 2.10, or 0.34 percent.
The share touched a 52-week high of Rs 640.00 and a 52-week low of Rs 412.05 on 25 March, 2026 and 07 April, 2025, respectively.
Currently, the stock is trading 2.95 percent below its 52-week high and 50.75 percent above its 52-week low.
The market capitalisation of the company stands at Rs 15,391.91 crore.
0 Comment